S
Sina Bavari
Researcher at United States Army Medical Research Institute of Infectious Diseases
Publications - 353
Citations - 21495
Sina Bavari is an academic researcher from United States Army Medical Research Institute of Infectious Diseases. The author has contributed to research in topics: Ebola virus & Virus. The author has an hindex of 69, co-authored 349 publications receiving 18782 citations. Previous affiliations of Sina Bavari include University of Nebraska Medical Center & Walter Reed Army Institute of Research.
Papers
More filters
Journal ArticleDOI
Discovering drugs for the treatment of Ebola virus
TL;DR: The gravity of the 2014-2016 outbreak spurred a heightened effort to identify and develop new treatments for Ebola virus disease, including small molecules, immunotherapeutics, host factors, and clinical disease management options.
Journal ArticleDOI
A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype A metalloprotease.
James C. Burnett,Dejan Opsenica,Kamaraj Sriraghavan,Rekha G. Panchal,Gordon Ruthel,Ann R. Hermone,Tam Luong Nguyen,Tara Kenny,Douglas Lane,Connor F. McGrath,James J. Schmidt,Jonathan L. Vennerstrom,Rick Gussio,Bogdan A. Šolaja,Sina Bavari +14 more
TL;DR: Four new, potent inhibitors of a structurally diverse small molecule (non-peptidic) inhibitors of the botulinum neurotoxin serotype A (BoNT/A) light chain (LC) are identified, supporting the structure-based pharmacophore contribution to inhibition.
Journal ArticleDOI
Standardization of the Filovirus Plaque Assay for Use in Preclinical Studies
Amy C. Shurtleff,Julia E. Biggins,Ashley E. Keeney,Elizabeth E. Zumbrun,Holly A. Bloomfield,Ana I. Kuehne,Jennifer L. Audet,Kendra J. Alfson,Anthony Griffiths,Gene G. Olinger,Sina Bavari +10 more
TL;DR: An evaluation of the conditions under which the filovirus plaque assay performs best for the Ebola virus Kikwit variant and the Angola variant of Marburg virus results in a plaque assay protocol which can be used for preclinical studies, and as a standardized protocol for use across institutions, to aid in data comparison.
Cross-Reactive Antibodies Prevent the Lethal Effects of Staphylococcus Aureus Superantigens
TL;DR: Immunizations with 1 SAg can induce cross-protective antibodies to heterologous SAgs, and multicomponent vaccination can enhance antibody responses against each bacterial SAg.
Journal ArticleDOI
Homologous and Heterologous Protection of Nonhuman Primates by Ebola and Sudan Virus-Like Particles
Kelly L. Warfield,John M. Dye,Jay Wells,Robert C. Unfer,Frederick W. Holtsberg,Sergey Shulenin,Hong Vu,Dana L. Swenson,Sina Bavari,M. Javad Aman +9 more
TL;DR: Using the EBOV nonhuman primate model, it is shown that one or two doses of VLP vaccine can confer protection from lethal infection and this observation provides strong evidence that it will be possible to develop and administer a broad-spectrum VLP-based vaccine that will protect against multiple filoviruses by combining only three E BOV, SUDV and MARV components.